$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

$rigl Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913080831 Filed on November 05, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$5.750M	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.650M	$4.680M	$5.380M
YoY Change	-20.51%	-13.01%	5.91%
% of Gross Profit
Research & Development	$18.05M	$17.57M	$20.19M
YoY Change	-8.65%	-12.94%	16.57%
% of Gross Profit
Depreciation & Amortization	$650.0K	$640.0K	$640.0K
YoY Change	3.17%	0.0%	25.49%
% of Gross Profit
Operating Expenses	$22.69M	$17.57M	$20.19M
YoY Change	-11.44%	-12.94%	16.57%
Operating Profit		-$23.93M	-$25.57M
YoY Change		-6.41%	41.73%
Interest Expense	$80.00K	$110.0K	$110.0K
YoY Change	-42.86%	0.0%	2650.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$16.86M	-$23.82M	-$25.46M
YoY Change	-33.8%	-6.44%	42.0%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.86M	-$23.82M	-$25.46M
YoY Change	-33.8%	-6.44%	42.0%
Net Earnings / Revenue	-293.22%
Basic Earnings Per Share			-$0.36
Diluted Earnings Per Share	-$192.8K	-$272.4K	-$0.36
COMMON SHARES
Basic Shares Outstanding	87.43M shares		71.64M shares
Diluted Shares Outstanding			71.64M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$212.0M	$230.9M	$183.9M
YoY Change	-28.92%	25.56%	-30.79%
Cash & Equivalents	$20.85M	$16.00M	$26.80M
Short-Term Investments	$191.1M	$214.9M	$157.1M
Other Short-Term Assets	$2.400M	$2.100M	$2.700M
YoY Change	-42.86%	-22.22%	-6.9%
Inventory
Prepaid Expenses
Receivables	$5.750M
Other Receivables	$0.00
Total Short-Term Assets	$220.1M	$233.0M	$186.6M
YoY Change	-27.24%	24.85%	-30.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.455M	$4.938M	$5.861M
YoY Change	-23.53%	-15.75%	12.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.528M	$1.586M	$1.826M
YoY Change	-13.13%	-13.14%	-10.93%
Total Long-Term Assets	$5.983M	$6.524M	$7.687M
YoY Change	-21.12%	-15.13%	5.69%
TOTAL ASSETS
Total Short-Term Assets	$220.1M	$233.0M	$186.6M
Total Long-Term Assets	$5.983M	$6.524M	$7.687M
Total Assets	$226.1M	$239.5M	$194.3M
YoY Change	-27.09%	23.27%	-29.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.903M	$1.025M	$1.388M
YoY Change	129.99%	-26.15%	8.86%
Accrued Expenses	$5.200M	$6.200M	$8.700M
YoY Change	-46.94%	-28.74%	24.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.29M	$8.303M	$10.59M
YoY Change	-15.65%	-21.56%	25.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$74.00K	$80.00K	$102.0K
YoY Change	-22.92%	-21.57%	-17.07%
Total Long-Term Liabilities	$74.00K	$80.00K	$102.0K
YoY Change	-22.92%	-21.57%	-17.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.29M	$8.303M	$10.59M
Total Long-Term Liabilities	$74.00K	$80.00K	$102.0K
Total Liabilities	$10.37M	$8.383M	$10.69M
YoY Change	-15.71%	-21.56%	25.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$849.3M	-$832.4M	-$734.8M
YoY Change	11.71%	13.29%	15.6%
Common Stock	$1.057B	$1.056B	$909.5M
YoY Change	0.78%	16.08%	1.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$208.3M	$223.4M	$174.8M
YoY Change
Total Liabilities & Shareholders Equity	$226.1M	$239.5M	$194.3M
YoY Change	-27.09%	23.27%	-29.56%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$16.86M	-$23.82M	-$25.46M
YoY Change	-33.8%	-6.44%	42.0%
Depreciation, Depletion And Amortization	$650.0K	$640.0K	$640.0K
YoY Change	3.17%	0.0%	25.49%
Cash From Operating Activities	-$18.90M	-$20.75M	-$19.63M
YoY Change	-12.38%	5.71%	53.48%
INVESTING ACTIVITIES
Capital Expenditures	-$170.0K	-$120.0K	-$390.0K
YoY Change	-71.67%	-69.23%	-30.36%
Acquisitions
YoY Change
Other Investing Activities	$23.67M	$15.03M	$19.46M
YoY Change	-121.98%	-22.76%	-277.88%
Cash From Investing Activities	$23.50M	$14.91M	$19.08M
YoY Change	-121.7%	-21.86%	-266.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	230.0K	0.000	1.200M
YoY Change	-99.83%	-100.0%	5900.0%
NET CHANGE
Cash From Operating Activities	-18.90M	-20.75M	-19.63M
Cash From Investing Activities	23.50M	14.91M	19.08M
Cash From Financing Activities	230.0K	0.000	1.200M
Net Change In Cash	4.830M	-5.840M	650.0K
YoY Change	-27.69%	-998.46%	-102.68%
FREE CASH FLOW
Cash From Operating Activities	-$18.90M	-$20.75M	-$19.63M
Capital Expenditures	-$170.0K	-$120.0K	-$390.0K
Free Cash Flow	-$18.73M	-$20.63M	-$19.24M
YoY Change	-10.68%	7.22%	57.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	8000	USD
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13822000	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15725000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15725000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13832000	shares
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2063000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3245000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5603000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9354000	USD
CY2012Q4	rigl	Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent	298241000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33484000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	264757000	USD
CY2013Q3	rigl	Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent	230882000	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	214851000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	273972000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	135000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	53000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure	274054000	USD
CY2013Q3	rigl	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	216222000	USD
CY2013Q3	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	137000	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2131000	USD
CY2013Q3	rigl	Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure	216351000	USD
CY2013Q3	rigl	Cash Equivalents And Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	183088000	USD
CY2013Q3	rigl	Cash Equivalents And Available For Sale Securities Debt Maturities Rolling Year Two Fair Value CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoFairValue	33263000	USD
	rigl	Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod	P218D
	rigl	Available For Sale Securities Debt Securities Current Stated Maturity Period May Be Greater Than This Period AvailableForSaleSecuritiesDebtSecuritiesCurrentStatedMaturityPeriodMayBeGreaterThanThisPeriod	P1Y
CY2013Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	16500000	USD
CY2013Q3	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2	0	USD
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2	0	USD
CY2013Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions	14	item
CY2013Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	31263000	USD
CY2013Q3	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	8000	USD
	dei	Entity Registrant Name EntityRegistrantName	RIGEL PHARMACEUTICALS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001034842
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87430342	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4217000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5826000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1759000	USD
CY2012Q4	us-gaap	Assets Assets	310043000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1697000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6775000	USD
CY2012Q4	rigl	Accrued Research And Development Liability Current AccruedResearchAndDevelopmentLiabilityCurrent	2124000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	942000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	666000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12204000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8647000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	96000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	87000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1049174000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	82000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-760247000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	289096000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	310043000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	87000	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1055599000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	129000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-832413000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	223402000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	239537000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1025000	USD
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2874000	USD
CY2013Q3	rigl	Accrued Research And Development Liability Current AccruedResearchAndDevelopmentLiabilityCurrent	2679000	USD
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	652000	USD
CY2013Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1073000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8303000	USD
CY2013Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7752000	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	80000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	233013000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4938000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1586000	USD
CY2013Q3	us-gaap	Assets Assets	239537000	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17574000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4677000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	23930000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23930000	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	106000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23824000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87430000	shares
CY2012Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	20186000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5383000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	25569000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-25569000	USD
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	113000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25456000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71636000	shares
	us-gaap	Contracts Revenue ContractsRevenue	1400000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	57282000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14964000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	73925000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72525000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	359000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-72166000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.83
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87240000	shares
	us-gaap	Contracts Revenue ContractsRevenue	2250000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	59014000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16997000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	76011000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-73761000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	393000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-73368000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71505000	shares
CY2013Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	112000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23712000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25387000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72119000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1941000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5603000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2086000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-173000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-672000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3901000	USD
	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	555000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-290000	USD
	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-504000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-67175000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	276328000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	309802000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	16479000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1053000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	48900000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	822000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	822000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-17453000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1797000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9354000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	141000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-165000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-168000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1872000	USD
	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	203000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	493000	USD
	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-101000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-63638000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	282813000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	354826000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2776000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	69237000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2569000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2569000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	8168000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18633000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26801000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">             </font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Nature of Operations</font></b></p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We were incorporated in the state of Delaware on June 14, 1996. We are engaged in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.</font></p> </div>
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">             </font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Basis of Presentation</font></b></p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Our accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet at December 31, 2012 has been derived from audited financial statements at that date, but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</font></p> </div>
CY2013Q3	us-gaap	Restructuring Charges RestructuringCharges	1679000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1679000	USD
CY2013Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.18	pure
CY2013Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	30	item
	rigl	Share Based Compensation Arrangement By Share Based Payment Award Exercise Period Of Vested Options For Terminated Employees Excluding Employee Covered Under Restructuring ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePeriodOfVestedOptionsForTerminatedEmployeesExcludingEmployeeCoveredUnderRestructuring	P90D
	rigl	Number Of Terminated Employees Whose Vesting Period For Unvested Stock Option Accelerated NumberOfTerminatedEmployeesWhoseVestingPeriodForUnvestedStockOptionAccelerated	1	item
CY2013Q3	us-gaap	Supplemental Unemployment Benefits Continuation Of Health Care SupplementalUnemploymentBenefitsContinuationOfHealthCare	171000	USD
CY2013Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	1500000	USD

Files In Submission

Name	View Source	Status
0001104659-13-080831-index-headers.html	Edgar Link	pending
0001104659-13-080831-index.html	Edgar Link	pending
0001104659-13-080831.txt	Edgar Link	pending
0001104659-13-080831-xbrl.zip	Edgar Link	pending
a13-19642_110q.htm	Edgar Link	pending
a13-19642_1ex31d1.htm	Edgar Link	pending
a13-19642_1ex31d2.htm	Edgar Link	pending
a13-19642_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rigl-20130930.xml	Edgar Link	completed
rigl-20130930.xsd	Edgar Link	pending
rigl-20130930_cal.xml	Edgar Link	unprocessable
rigl-20130930_def.xml	Edgar Link	unprocessable
rigl-20130930_lab.xml	Edgar Link	unprocessable
rigl-20130930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

2013 Q4 Form 10-Q Financial Statement

#000110465913080831 Filed on November 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL RIGEL PHARMACEUTICALS INC Stock $rigl

2013 Q4 Form 10-Q Financial Statement

#000110465913080831 Filed on November 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl